Adalimumab Drug Level ELISA
$1,053.00
Catalog
30-ADLHU-E01
The Adalimumab Drug Level ELISA is intended for the quantitative determination of free Humira® concentration in human serum and EDTA plasma.Health Canada Licensed , Research Use Only. Not for Use in Diagnostic Procedures.
Species
Human
Regulatory Status
Health Canada Licensed, Research Use Only. Not for Use in Diagnostic Procedures.
Product Distribution
Available in North America Only
Range
4.15 - 225 ng/mL
Sensitivity
4.15 ng/mL
Sizes
96 Wells
Sample Types
EDTA Plasma, Serum
Inc Time Hour
2
Inc Time Minute
20
Inc Time Overnight
No
Inc Time See Protocol
No
Sample Size
100
Detection
Colorimetric
This ELISA is designed to determine the quantity of free adalimumab (therapeutic antibody against TNF-alpha, HUMIRA®) in EDTA plasma or serum samples. In a first incubation step, the free adalimumab from the sample is bound to the specific monoclonal anti-adalimumab antibody coated on the plate. To remove all unbound substances, a washing step is carried out. In a further incubation step, peroxidase-labeled antibody is added. Following a second wash step, tetramethylbenzidine (TMB) is used as a substrate for peroxidase. Finally, an acidic stop solution is added to terminate the reaction. The color changes from blue to yellow. The intensity of the yellow color is directly proportional to the concentration of free adalimumab in the sample. A dose response curve of the absorbance unit (optical density, OD) versus concentration is generated, using the values obtained from the standard curve. The concentrations of free adalimumab in the samples are determined directly from this curve.
